title: mu-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization.
abstract: Repeated administration of psychostimulants to rodents can lead to behavioral sensitization. Previous studies, using nonspecific opioid receptor (OR) antagonists, revealed that ORs were involved in modulation of behavioral sensitization to methamphetamine (METH). However, the contribution of OR subtypes remains unclear. In the present study, using mu-OR knockout mice, we examined the role of mu-OR in the development of METH sensitization. Mice received daily intraperitoneal injection of drug or saline for 7 consecutive days to initiate sensitization. To express sensitization, animals received one injection of drug (the same as for initiation) or saline on day 11. Animal locomotor activity and stereotypy were monitored during the periods of initiation and expression of sensitization. Also, the concentrations of METH and its active metabolite amphetamine in the blood were measured after single and repeated administrations of METH. METH promoted significant locomotor hyperactivity at low doses and stereotyped behaviors at relative high doses (2.5 mg/kg and above). Repeated administration of METH led to the initiation and expression of behavioral sensitization in wild-type mice. METH-induced behavioral responses were attenuated in the mu-OR knockout mice. Haloperidol (a dopamine receptor antagonist) showed a more potent effect in counteracting METH-induced stereotypy in the mu-OR knockout mice. Saline did not induce behavioral sensitization in either genotype. No significant difference was observed in disposition of METH and amphetamine between the two genotypes. Our study indicated that the mu-opioid system is involved in modulating the development of behavioral sensitization to METH. (c) 2010 Wiley-Liss, Inc.
authors.affiliation: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216-4500, USA.
authors.forename: Xine
authors.initials: X
authors.lastname: Shen
authors.forename: Chris
authors.initials: C
authors.lastname: Purser
authors.forename: Lu-Tai
authors.initials: LT
authors.lastname: Tien
authors.forename: Chi-Tso
authors.initials: CT
authors.lastname: Chiu
authors.forename: Ian A
authors.initials: IA
authors.lastname: Paul
authors.forename: Rodney
authors.initials: R
authors.lastname: Baker
authors.forename: Horace H
authors.initials: HH
authors.lastname: Loh
authors.forename: Ing K
authors.initials: IK
authors.lastname: Ho
authors.forename: Tangeng
authors.initials: T
authors.lastname: Ma
mesh_terms: D017109:Akathisia, Drug-Induced / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D000661:Amphetamine / Q000097:blood; D000818:Animals; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects; D017450:Receptors, Opioid, mu / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D013239:Stereotyped Behavior / Q000187:drug effects
chemical_list: D000697:Central Nervous System Stimulants; D018492:Dopamine Antagonists; D017450:Receptors, Opioid, mu; D008694:Methamphetamine; D000661:Amphetamine; D006220:Haloperidol